According to the province’s Chief Medical Officer of Health, an Alberta woman has died in her 50s after receiving the AstraZeneca COVID-19 vaccine.
In a news release Tuesday night, Drs. Dina Hinsav said the malignancy was confirmed to be “associated with vaccine-induced immune thrombotic thrombocytopenia (VITT).”
Hinshaw said for reasons of patient confidentiality, he would not provide additional case information.
“While any death is tragic, it is important to remember that the risk of dying from COVID-19 or suffering other serious consequences far exceeds the later risk of the AstraZeneca vaccine,” she said.
“The Alberta case marks the second VITT case and out of more than 253,000 doses of AstraZeneca or Covicheld / AstraZeneca, is the only VITT-related death that has been administered in Alberta to date.”
READ MORE: Alberta doctors say 300 COVID-19 patients will increase in ICU by end of May
Hinshaw stated that the global frequency of VITT has been estimated in approximately one case at 100,000 to 250,000 doses of the AstraZeneca vaccine.
‘It may be murder’: Legal experts warn about hosting parties during COVID-19
Ontario man takes car to Nissan dealership for repair, app shows it was taken for 90 km journey
“In comparison, Alberts 50 to 59 who are diagnosed with COVID-19 are 350 times more likely to die of that infection than those who experience VITT after the AstraZeneca vaccine. They are at least 1,500 times more likely to be hospitalized with COVID-19 than have experienced VITT after receiving AstraZeneca. “
READ MORE: Blood clot risk: COVED-19 vaccine compares to common drugs, travel and smoking
Last month, Canada reported its first case of a rare blood clot in a person who had received the AstraZeneca Kovid-19 vaccine.
A Quebec woman died in late April, becoming the first Canadian to die in this condition after receiving the vaccine.
See below: Some global news videos about the AstraZeneca COVID-19 vaccine
View link »
© 2021 Global News, a division of Chorus Entertainment Inc.